The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Effect of delays in the 2-week-wait cancer referral pathway during the COVID-19 pandemic on cancer survival in the UK: a modelling study
Open accessAbstract
Background During the COVID-19 lockdown, referrals via the 2 Week Wait (2WW) urgent pathway for suspected cancer in England are reported to have dropped by up to 84%. We aimed to examine the impact on cancer survival of different scenarios of lockdown-accumulated-backlog. We also aimed to examine by tumour-referral-group and age, survival benefit per referred patient considering survival decrement from delayed referral versus risk of death from nosocomial SARS-CoV-2 infection. Methods To construct the underlying models, we used age- and stage-stratified 10 year-cancer survival estimates for England 2007-2017 for 20 common tumour-types. We applied per-day hazard ratios for cancer progression generated from observational studies of delay-to-treatment. We quantified the annual numbers of cancers diagnosed via the 2WW-pathway using the 2WW age- and stage-specific breakdowns. From these, for per-patient delays of 1-6 months, we estimated aggregate number of lives lost and life-years lost in England. Using referral-to-diagnosis conversion rates and COVID-19 case fatality rates, we also estimated the survival increment per patient referred. Findings Per month across England in 2013-2016, on average 6,281 patients with Stage 1-3 cancer were diagnosed via the 2WW pathway of whom 1,691 would be predicted to die within 10 years from their disease. We estimated 2WW-pathway presentational-delay from three months of lockdown will result in total in 181/361/542 attributable additional deaths (if % reduction in referrals was 25/50/75% respectively). Limited diagnostic capacity to address the backlog may result in additional delays: 401/811/1,231 attributable additional deaths are estimated if additional diagnostic capacity is delayed until months 3-8 post-lockdown. 2-month delay in 2WW investigatory referral results in average loss of life-years per-referred-patient of between 0 and 0.7, depending on age and tumour-type. Interpretation Prompt provision of additional capacity for ‘catch-up’ in diagnostics will minimise deaths consequent from ‘diagnostic-delay’ accumulated on top of the ‘presentational-delay’. Prioritisation of patient groups for whom delay would result in most life-years lost warrants consideration as an option for mitigating the aggregate burden of mortality.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Docherty, A. B., Harrison, E. M., Green, C. A., Hardwick, H. E., Pius, R., Norman, L., Holden, K. A., Read, J. M., Dondelinger, F., Carson, G., et al. (2020) · BMJ · doi:10.1136/bmj.m1985 · Cited by 3,481 · cited 2×
“…the patient a year of ‘active cancer management’ status; this was the product of the likelihood of community-acquired COVID-19 during the year (1%, 10%, 20%, 50%), age-specific case fatality rates and increase in COVID CFR as a consequence of cancer as a co-morbidity (2-times, 5-times) (11, 12).”
CDC Weekly, C., & The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team (2020) · China CDC Weekly · doi:10.46234/ccdcw2020.032 · Cited by 2,889
The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team (2020) · PubMed Central · Cited by 1,278
Influence of delay on survival in patients with breast cancer: a systematic review
Richards, M., Westcombe, A., Love, S., Littlejohns, P., & Ramirez, A. (1999) · The Lancet · doi:10.1016/s0140-6736(99)02143-1 · Cited by 1,171
Wilkinson, E. (2002) · The Lancet Oncology · doi:10.1016/s1470-2045(02)00737-4 · Cited by 951
Fewer cancer diagnoses during the COVID-19 epidemic in the Netherlands
Dinmohamed, A. G., Visser, O., Verhoeven, R. H. A., Louwman, M. W. J., van Nederveen, F. H., Willems, S. M., Merkx, M. A. W., Lemmens, V. E. P. P., Nagtegaal, I. D., & Siesling, S. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30265-5 · Cited by 699
Time to Surgery and Breast Cancer Survival in the United States
Bleicher, R. J., Ruth, K., Sigurdson, E. R., Beck, J. R., Ross, E., Wong, Y.-N., Patel, S. A., Boraas, M., Chang, E. I., Topham, N. S., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2015.4508 · Cited by 609
Collateral damage: the impact on outcomes from cancer surgery of the COVID-19 pandemic
Sud, A., Jones, M. E., Broggio, J., Loveday, C., Torr, B., Garrett, A., Nicol, D. L., Jhanji, S., Boyce, S. A., Gronthoud, F., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.05.009 · Cited by 552
Self-citationRisk of Perforation After Colonoscopy and Sigmoidoscopy: A Population-Based Study
Gatto, N. M., Frucht, H., Sundararajan, V., Jacobson, J. S., Grann, V. R., & Neugut, A. I. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.3.230 · Cited by 522
Lai, A. G., Pasea, L., Banerjee, A., Hall, G., Denaxas, S., Chang, W. H., Katsoulis, M., Williams, B., Pillay, D., Noursadeghi, M., et al. (2020) · BMJ Open · doi:10.1136/bmjopen-2020-043828 · Cited by 447
Self-citation
Cited by
Glasbey, J., Ademuyiwa, A., Adisa, A., AlAmeer, E., Arnaud, A. P., Ayasra, F., Azevedo, J., Minaya-Bravo, A., Costas-Chavarri, A., Edwards, J., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00493-9 · Cited by 287
Self-citationImpact of COVID-19 on cancer care in India: a cohort study
Ranganathan, P., Sengar, M., Chinnaswamy, G., Agrawal, G., Arumugham, R., Bhatt, R., Bilimagga, R., Chakrabarti, J., Chandrasekharan, A., Chaturvedi, H. K., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00240-0 · Cited by 159
Acute surgical abdomen during the COVID 19 pandemic: Clinical and therapeutic challenges
Serban, D., Socea, B., Badiu, C., Tudor, C., Balasescu, S., Dumitrescu, D., Trotea, A., Spataru, R., Vancea, G., Dascalu, A., et al. (2021) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2021.9950 · Cited by 39
Metadata
- Authors
- Sud, A., Torr, B., Jones, M. E., Broggio, J., Scott, S., Loveday, C., Garrett, A., Gronthoud, F., Nicol, D. L., Jhanji, S., Boyce, S. A., Williams, M., Riboli, E., Muller, D. C., Kipps, E., Larkin, J., Navani, N., Swanton, C., Lyratzopoulos, G., McFerran, E., Lawler, M., Houlston, R., & Turnbull, C.
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2020-08
- Volume
- 21
- Issue
- 8
- Pages
- 1035-1044
- ISSN
- 1470-2045 (ISSN-L)
- OpenAlex
- W3042357937
- Cited by
- 484
- References
- 16
- FWCI
- 29.67
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of delays in the 2-week-wait cancer referral pathway during the COVID-19 pandemic on cancer survival in the UK: a modelling study. https://app.cochat.ai/papers/10.1016/s1470-2045(20)30392-2
- The paper
- Sud, A., Torr, B., Jones, M. E., Broggio, J., Scott, S., Loveday, C., Garrett, A., Gronthoud, F., Nicol, D. L., Jhanji, S., Boyce, S. A., Williams, M., Riboli, E., Muller, D. C., Kipps, E., Larkin, J., Navani, N., Swanton, C., Lyratzopoulos, G., . . . Turnbull, C. (2020). Effect of delays in the 2-week-wait cancer referral pathway during the COVID-19 pandemic on cancer survival in the UK: a modelling study. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(20)30392-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.